Medivolve Inc. (MEDVF)
USD 0.01
(133.33%)
USD 0.01
(133.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 866.02 Thousand CAD | 132.77% |
| 2022 | -2.64 Million CAD | -255.14% |
| 2021 | 1.7 Million CAD | -91.2% |
| 2020 | 19.35 Million CAD | 1983520.39% |
| 2019 | -976.00 CAD | 99.98% |
| 2018 | -4.37 Million CAD | 9.49% |
| 2017 | -4.83 Million CAD | -301.39% |
| 2016 | -1.2 Million CAD | -2138.7% |
| 2015 | -53.84 Thousand CAD | 75.85% |
| 2014 | -222.99 Thousand CAD | 73.91% |
| 2013 | -854.66 Thousand CAD | 75.07% |
| 2012 | -3.42 Million CAD | 46.97% |
| 2011 | -6.46 Million CAD | -114.16% |
| 2010 | -3.01 Million CAD | 51.16% |
| 2009 | -6.18 Million CAD | -564.69% |
| 2008 | -929.86 Thousand CAD | -165.73% |
| 2007 | -349.92 Thousand CAD | -6072.5% |
| 2006 | 5859.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.4 Million CAD | 62.57% |
| 2023 Q3 | 194.07 Thousand CAD | 133.58% |
| 2023 Q4 | 866.02 Thousand CAD | 346.23% |
| 2023 Q1 | -341.57 Thousand CAD | 87.07% |
| 2023 FY | 866.02 Thousand CAD | 132.77% |
| 2023 Q2 | -577.97 Thousand CAD | -69.21% |
| 2022 Q2 | -3.27 Million CAD | 49.38% |
| 2022 Q4 | -2.64 Million CAD | 46.72% |
| 2022 Q3 | -4.95 Million CAD | -51.57% |
| 2022 FY | -2.64 Million CAD | -255.14% |
| 2022 Q1 | -6.46 Million CAD | -479.53% |
| 2021 FY | 1.7 Million CAD | -91.2% |
| 2021 Q1 | 8.95 Million CAD | -53.74% |
| 2021 Q3 | 1.01 Million CAD | -90.58% |
| 2021 Q4 | 1.7 Million CAD | 67.85% |
| 2021 Q2 | 10.77 Million CAD | 20.28% |
| 2020 Q3 | 12.03 Million CAD | -5.6% |
| 2020 FY | 19.35 Million CAD | 1983520.39% |
| 2020 Q1 | -1.32 Million CAD | -136107.17% |
| 2020 Q2 | 12.75 Million CAD | 1059.12% |
| 2020 Q4 | 19.35 Million CAD | 60.84% |
| 2019 Q4 | -976.00 CAD | 99.82% |
| 2019 Q2 | -2.53 Million CAD | 19.48% |
| 2019 Q3 | -530.73 Thousand CAD | 79.06% |
| 2019 Q1 | -3.14 Million CAD | 28.13% |
| 2019 FY | -976.00 CAD | 99.98% |
| 2018 Q3 | -4.68 Million CAD | 3.39% |
| 2018 Q2 | -4.84 Million CAD | -4.01% |
| 2018 Q1 | -4.66 Million CAD | 3.69% |
| 2018 FY | -4.37 Million CAD | 9.49% |
| 2018 Q4 | -4.37 Million CAD | 6.48% |
| 2017 Q1 | -878.56 Thousand CAD | 27.12% |
| 2017 Q3 | -456.93 Thousand CAD | 13.6% |
| 2017 Q4 | -4.83 Million CAD | -958.96% |
| 2017 Q2 | -528.85 Thousand CAD | 39.81% |
| 2017 FY | -4.83 Million CAD | -301.39% |
| 2016 Q4 | -1.2 Million CAD | 19.43% |
| 2016 FY | -1.2 Million CAD | -2138.7% |
| 2016 Q1 | -60.24 Thousand CAD | -11.88% |
| 2016 Q2 | -45.87 Thousand CAD | 23.85% |
| 2016 Q3 | -1.49 Million CAD | -3161.24% |
| 2015 Q4 | -53.84 Thousand CAD | 10.0% |
| 2015 Q2 | -11.45 Thousand CAD | 82.72% |
| 2015 Q1 | -66.27 Thousand CAD | 70.28% |
| 2015 FY | -53.84 Thousand CAD | 75.85% |
| 2015 Q3 | -59.83 Thousand CAD | -422.51% |
| 2014 Q3 | -147.92 Thousand CAD | 57.97% |
| 2014 Q1 | -318 Thousand CAD | 62.79% |
| 2014 FY | -222.99 Thousand CAD | 73.91% |
| 2014 Q2 | -351.93 Thousand CAD | -10.67% |
| 2014 Q4 | -222.99 Thousand CAD | -50.75% |
| 2013 Q4 | -854.66 Thousand CAD | 23.73% |
| 2013 FY | -854.66 Thousand CAD | 75.07% |
| 2013 Q3 | -1.12 Million CAD | 27.17% |
| 2013 Q2 | -1.53 Million CAD | 35.42% |
| 2013 Q1 | -2.38 Million CAD | 30.51% |
| 2012 Q3 | -4.44 Million CAD | 13.03% |
| 2012 FY | -3.42 Million CAD | 46.97% |
| 2012 Q2 | -5.11 Million CAD | 11.72% |
| 2012 Q4 | -3.42 Million CAD | 22.87% |
| 2012 Q1 | -5.78 Million CAD | 10.45% |
| 2011 Q2 | -8.21 Million CAD | -227.86% |
| 2011 Q1 | -2.5 Million CAD | 17.04% |
| 2011 FY | -6.46 Million CAD | -114.16% |
| 2011 Q4 | -6.46 Million CAD | 13.75% |
| 2011 Q3 | -7.49 Million CAD | 8.71% |
| 2010 FY | -3.01 Million CAD | 51.16% |
| 2010 Q3 | -3.39 Million CAD | 13.13% |
| 2010 Q2 | -3.91 Million CAD | 19.38% |
| 2010 Q1 | -4.85 Million CAD | 21.51% |
| 2010 Q4 | -3.01 Million CAD | 11.15% |
| 2009 Q3 | -6.44 Million CAD | -431.65% |
| 2009 Q2 | -1.21 Million CAD | -102.49% |
| 2009 Q1 | -598.68 Thousand CAD | 35.62% |
| 2009 FY | -6.18 Million CAD | -564.69% |
| 2009 Q4 | -6.18 Million CAD | 4.1% |
| 2008 Q1 | -320.84 Thousand CAD | 8.31% |
| 2008 Q2 | -249.41 Thousand CAD | 22.26% |
| 2008 FY | -929.86 Thousand CAD | -165.73% |
| 2008 Q4 | -929.86 Thousand CAD | 33.55% |
| 2008 Q3 | -1.39 Million CAD | -461.05% |
| 2007 Q1 | 1212.00 CAD | -79.31% |
| 2007 Q2 | 1951.00 CAD | 60.97% |
| 2007 Q3 | -394.17 Thousand CAD | -20303.49% |
| 2007 Q4 | -349.92 Thousand CAD | 11.22% |
| 2007 FY | -349.92 Thousand CAD | -6072.5% |
| 2006 FY | 5859.00 CAD | 0.0% |
| 2006 Q4 | 5859.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 60.742% |
| Arrayit Corporation | 1.05 Million USD | 17.957% |
| Atlantic International Corp. | 236.49 Thousand USD | -266.191% |
| Biocept, Inc. | -788 Thousand USD | 209.902% |
| Bioqual, Inc. | -12 Million USD | 107.213% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -3708.549% |
| DermTech, Inc. | 17.65 Million USD | 95.094% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 100.151% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 111.74% |
| iMD Companies, Inc. | 1.11 Million USD | 22.393% |
| IDenta Corp. | 524.85 Thousand USD | -65.004% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 88.744% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 3313.216% |
| InVitro International | -313.14 Thousand USD | 376.56% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 44.695% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 121562.272% |
| Medical Imaging Corp. | 3.79 Million USD | 77.155% |
| NovelStem International Corp. | 3.52 Million USD | 75.408% |
| Optigenex Inc. | 8.93 Million USD | 90.306% |
| PharmChem, Inc. | -1.49 Million USD | 157.951% |
| Proteome Sciences plc | 14.57 Million USD | 94.057% |
| Response Genetics, Inc | -13.08 Million USD | 106.618% |
| Rennova Health, Inc. | 14.82 Million USD | 94.16% |
| RushNet, Inc. | 4.8 Million USD | 81.961% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -538.714% |
| Stella Diagnostics Inc. | 6.19 Million USD | 86.016% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 51.467% |
| Todos Medical Ltd. | 38.31 Million USD | 97.74% |